The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Overall survival of patients following treatment with luspatercept in the MEDALIST trial
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the importance of evaluating overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS), highlighting results from the MEDALIST trial (NCT02631070). In this study, patients treated with luspatercept demonstrated an improvement in OS, and Prof. Santini highlights the need for longer follow-ups to further assess OS benefits in patients with LR-MDS. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis, AbbVie, BMS, Gilead, Menarini, Geron, Otsuka: Honoraria.
